RxDoctor Payments Data

Hector Rojas Martinez

Ophthalmology · Clinton, MDNPI 1861949745

Payments from drug & device makers

$2,294in general payments, 2019–2025

Across 98 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$363
  • Bausch & Lomb Americas Inc.$339
  • Alcon$338
  • Sun Pharmaceutical Industries Inc.$321
  • Sight Sciences, Inc.$267
  • Oyster Point Pharma, Inc.$241
  • plus $424 from 8 others

What the payments were for

  • Food & beverage$2,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,294 in reported general payments places this provider in the 60th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$358,792
Medicare patients
754
Services billed
2,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine77$98,282
XiidraLifitegrast36$51,944
LumiganBimatoprost20$15,040
Cyclosporine29$14,943
Latanoprost220$3,276
Prednisolone Acetate52$2,914
Travoprost17$2,202
Timolol Maleate32$1,741
ErythromycinErythromycin Base127$1,347
Ketorolac Tromethamine42$1,092
Brimonidine Tartrate29$857
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$726
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$407
Ciprofloxacin Hcl16$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$91$113,32297 claims
Bausch & Lomb Americas Inc.Xiidra$339$51,94436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →